Centro Hospital Universitario Dr. Preset

Valencia 46017

1 studies enrolling now · 3 studies all time

What they study most

Antibody-mediated Rejection, Early Alzheimer's Disease, End Stage Kidney Disease

Studies at this site

• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects — Completed
• Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients — Stopped early